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ABSTRACT
Functionality Of The Gracilis Collateral Is Impaired
Following Arteriogenesis And Cell Transplantation
Ada Azucena Tadeo

Peripheral Arterial Disease involves narrowed arteries, reducing blood flow to limbs. Increasing
blood flow to those extremities is possible by redirecting the blood to flow through natural
bypasses (i.e. collateral arteries), which can enlarge via arteriogenesis to maintain blood supply
once the prominent arteries have become occluded. This study aims to investigate how
arteriogenesis affects collateral function, if myoblast transplantation can stimulate collateral
growth, and how that in turn may affect collateral function. Femoral artery ligation was
performed to mimic the blockage that occurs in patients with ischemic diseases on lean mice and
mice with diet induced obesity (DIO). A bioprinted polymer containing cells, or no cells, was
then placed deep to the primary collateral artery. Seven days post-surgery, the collateral bypass
artery was exposed and prepared for imaging. To quantify the functionality of the collaterals,
photomicrographs of the collaterals were captured from both the operated and control hindlimb
at rest and following muscle contraction via electrical stimulation. Results showed that
arteriogenesis occurred in lean mice and mice with DIO. Myoblasts decreased resting and dilated
diameter in mice with DIO as compared to vehicle control, meanwhile myoblasts increased
resting and dilated diameters in lean mice as compared to vehicle control. The percent difference
between resting and functionally vasodilated collaterals was measured to evaluate myoblast
impact on collateral vasodilation following arteriogenesis. It was found that myoblasts did not
make more arteriogenesis, but appeared to accelerate vessel maturation. This line of research can
ultimately lead to the development of an alternative, minimally invasive, therapy to treat patients
with ischemic diseases that would benefit from natural bypass enlargement and function.
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INTRODUCTION
Cardiovascular diseases are the leading cause of death
around the world, with approximately 17.9 million
casualties each year1. Peripheral Artery Occlusive
Disease (PAOD) is a common type of cardiovascular
disease that affects over 200 million people worldwide2-3
and 8-12 million Americans4-5. This disease is not
characterized as affecting one sex more than the other,
however differences are seen between racial/ethnic
groups, with an increasing prevalence of PAOD in
African Americans and slightly higher rates in Hispanic

Figure 1. Blood flow in normal versus
atherosclerotic artery.
Peripheral Artery Occlusive Disease involves
narrowed arteries due to excessive
accumulation of plaque, restricting blood flow
and oxygen supply to lower extremities

people compared to non-Hispanic white people6. Risk factors of this disease include smoking,
high blood pressure, atherosclerosis, diabetes, high cholesterol, and age above 60 years6. In the
United States, PAOD affects as high as 10% of the population with 30%-40% of those patients
experiencing symptoms of intermittent claudication7. PAOD is caused by atherosclerosis of a
main prominent artery, such as the tibial artery (Figure 1). Narrowing of the prominent blood
vessel restricts blood flow and oxygen supply to the downstream tissues and can result in chronic
ischemia during physical activity or even at rest8. Patients with advanced PAOD and diabetes are
at a particularly higher risk for developing diabetic foot ulcers (DFU) with a lifetime prevalence
of up to 25%9, gangrene, and ultimately requiring an amputation. It is common in this US
population that people with PAOD do in fact receive amputations, up to 150,000 amputations
performed annually10, and the death rate for people who have been treated with lower extremity
amputation (LEA) are as high as 48% at 1 year and 71% at 3 years following surgery11.
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Current methods of treatment involve pharmacological and endovascular intervention that target
the main arteries containing the blockage. Anticoagulation medication and the percutaneous
insertion of stents/balloon catheters are few examples of these types of treatments; however, they
do not always lead to a better patient prognosis. For example, numerous anticoagulation
medication did not alleviate symptoms in PAOD patients12. Surgical treatments such as bypass
surgery, endarterectomy, and endovascular intervention are available for patients if disease
conditions do not improve with medication or lifestyle changes13. However, these procedures can
be invasive depending on occlusion size and location. Significant risks in treating PAOD with
bypass surgery include heart attacks, blood clots, infection, and death – which occurs in 2-3% of
cases14. Variations in vessel occlusion, luminal stenosis, and number of lesions, influence the
procedural approach of bypass surgery. In cases where the blockage extends for a substantial
length of the vessel, long incisions are often required, leading to as many as 20% of patients who
receive lower extremity bypass surgery to experience complications during recovery14. In
addition, follow up procedures to maintain the function of the grafts are required in up to one
third percent of all cases14. Technological improvements in medical devices involved with
endovascular intervention have been made in recent years with developments in drug-eluting
tools, biomimetic stents, and specialized balloon catheters15, however the risk factors associated
with these procedures, such as restenosis, calcification, silent embolism, and microvascular
disease, limit the potential for significant lasting treatment of revascularization15. Unfortunately,
up to 50% of patients receiving revascularization therapies experience failed treatment16.
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When stenosis occurs in a prominent artery, natural bypass vessels known as collateral arteries
enlarge due to the increase in shear stress against the vessel walls, resulting in increased blood
flow downstream (Figure 2). This enlargement process is defined as arteriogenesis – the outward
remodeling of preexisting vessels. The mechanisms of arteriogenesis are highlighted in Figure 3.
By providing this alternative pathway of blood supply,
collaterals can reduce the effects of ischemia for patients. A
focus for treating peripheral artery occlusive disease has
thus been shifted to stimulating growth of these natural
bypass collaterals. Studies involving the administration of
genes and proteins as a therapeutic intervention for
enhancing collateral growth proved to be successful in
Figure 2. Collateral arteriogenesis as a
natural bypass to re-route blood flow.
Collateral arteries naturally enlarge in
response to the occlusion of a prominent
blood vessel. This serves as a natural
bypass that re-routes the blood flow
around the occlusion to supply oxygen to
lower extremities.

animal models, however replication in human trials showed
no significant effect of the treatment17. Bone marrowderived cells were then utilized to determine their effectivity
in enhancing collateral development. Cell therapy rose as a

more promising treatment method due to its apparent paracrine role, the potential for the various
differentiated cell types to incorporate directly with the vessel walls of newly formed or
remodeled collaterals, however these hypotheses are continuing to be investigated in ongoing
studies18. Given the insufficiency of pharmacological and endovascular intervention, and the
potential for cell therapy as a means of treating patients with this disease, non-bone marrowderived cell therapy has emerged as a new treatment candidate.
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Preliminary data indicates that myoblasts enhance
arteriogenesis19. Myoblasts are of particular interest to
our group for their involvement in muscle fiber
regeneration. Myoblasts contain proteins that
coordinate membrane repair in addition to myoblast
fusion for muscle formation20. Myoblasts and
macrophages have been shown to interrelate with one
another when implanted into skeletal muscle21.
Myoblast survival, expansion, and migration
improved following implantation, offering a potential
therapeutic benefit for treatment of skeletal muscular
disease. The prospective ability for myoblast cells to

Figure 3. Arteriogenesis - the vascular
response to occlusion of prominent artery.
Blood flows normally through pre-existing
collateral vessels (A). Following occlusion of
prominent vessel, the collateral arteriole
experiences an increase in blood flow, increasing
shear stress on the vessel wall (B). Macrophages
guide outward remodeling of pre-existing
collateral vessels to equilibrate shear stress (C).
Adapted from Hendrikx et al., 2016.

control/be controlled by macrophages is especially
interesting because macrophages are primary regulators for arteriogenesis. This, combined with
their ability to interact with endothelial cells in angiogenic processes22, magnifies the importance
of investigating myoblasts as instrumental components to enhancing the mechanism of
arteriogenesis.
Vasodilation is a vascular response that is important to keep into consideration when
investigating enhanced arteriogenesis due to myoblast implantation. While our lab aims to
develop a therapy that alleviates symptoms of chronic ischemia, we are also cautious of
introducing any negative side effects. If collateral vasodilation and vasoconstriction is impaired,
tissues downstream of collaterals may suffer. Although myoblasts have been shown to enhance
arteriogenesis, it is still unclear how they affect vasodilation. Thus, a need for further studies on
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enlarged collateral functionality arose. In a study completed previously in this lab, loss of
vascular tone was determined to be associated with the arteriogenesis that occurred following the
ligation of the femoral artery in C57Bl/6 mice23. Therefore, this study will measure vascular tone
to determine if results are consistent. Investigating the functionality of vessels that have
undergone arteriogenesis can provide insight into the efficacy and safety of therapies that
stimulate collateral enhancement.
This study investigated the potential for myoblast as an effective method to enhancing the
enlargement of collateral arteries. The experiment was designed to address three questions:
(1) Do myoblasts lead to more arteriogenesis?
(2) Is collateral vasodilation impaired with changes in mouse phenotype? And
(3) Do myoblasts impact vasodilation following arteriogensis?
The methods necessary to answer this question involve the vasodilation procedure, femoral
artery ligation surgery, cell transplantation, and obese mouse models to represents patient
phenotype more accurately.

METHODS
Animals
All procedures involved in this study are approved by the Institutional Animal Care and Use
Committee (IACUC). Four-week-old C57BL/6 male mice (n=12) were received from The
Jackson Laboratory. Mice were housed in cages of 6 mice each, with access to food (14% protein
rodent maintenance diet) and water ad libitum, in a temperature and light controlled room (12hour light/dark cycle). Following a two-week acclimation period, the mice began a specialized
13

diet, control feed (10% fat) for lean mice (n=6), or treatment feed (60% fat) for mice with DIO
(n=6), mixed into the standard 6% fat mouse feed at a 1:1 ratio. After approximately 10 weeks
on this specialized diet, the study commenced. Following surgery, mice were returned to the
vivarium and housed in pairs with their respective feed until the 7-day assessment procedure.
Femoral Artery Ligation
To mimic the blockage that occurs in patients
with ischemic diseases, femoral artery
ligation was performed on mice. The ligation
site was identified as distal to the epigastric
and profunda arteries and proximal to the

Figure 4. Ligation of the femoral artery in C57LB/6 mice.
Untied suture looped underneath the femoral artery (A). Tied
suture ligating the femoral artery (B).

saphenous and popliteal arteries. Mice were
initially anesthetized in an induction chamber with 5% isofluorane in oxygen at a flow rate of
0.8-1.0 L/min. Once anesthetized, mice were weighed and moved to the preparation bench in a
supine position. Isofluorane was reduced to 1.5-3% for the remainder of the surgery. To prevent
corneal desiccation, veterinary ophthalmic ointment was applied on both eyes of the mice.
Depilatory cream was applied to both hindlimbs around the surgical area to remove hair. A
preoperative buprenorphine analgesic (0.075mg/kg) was administered subcutaneously via
injection prior to placing the mouse on the surgical stage. A temperature heat pad and thermal
rectal probe sustained mice body temperature at 35° C. Surgeons followed aseptic technique
protocols throughout the surgery. The femoral artery was isolated from the neurovascular bundle
and ligated with a 6-0 silk suture (Figure 4). A bio-printed construct containing myoblasts (n=6,
3 lean and 3 DIO) or no cells (n=6, 3 lean and 3 DIO) was then transplanted in a pocket
underneath the gracilis muscle (Figure 5)(Figure 7). Constructs were prepared in advance using
14

BioBot (Advanced Solutions) and are made from a
hydrogel mix of sodium alginate and pluronic f127. 7-0
polypropylene suture was used to close the incision.
The sham surgery was performed on the opposite
hindlimb, which involved the initial incision and blunt
dissection of tissue surrounding the neurovascular
bundle, without the isolation of the femoral artery.
Postoperative buprenorphine analgesic was then

Figure 5. Bio-printed construct placement.
A bio-printed construct (3mm diameter and
1mm height) containing myoblasts, or no cells
was implanted underneath the gracilis muscle
following the femoral artery ligation.

administered, and the mouse was placed in a recovery
bin until ambulatory. The postoperative analgesic was administered again each day for two days
following surgery.
Ambulation Scoring
To monitor hindlimb mobility following surgery, ambulation scoring was conducted.
Observations were made immediately after surgery, and on the first, second-, and seventh day
following surgery. Scores were determined using a scale of 0-3; 0 – normal movement, 1 –
dorsiflexion with some plantarflexion (mild limp), 2 – complete dorsiflexion (hobbling), 3 –
plantarflexion of hind paw (dragging).
Functional Vasodilation
Assessment of collateral arteriogenesis and functionality occurred 7 days following the femoral
artery ligation surgery. Mice were anesthetized and prepared as previously described. The
gracilis anterior muscle containing the primary hindlimb collateral artery was exposed and
prepared for imaging. The bio-printed construct was located from underneath the gracilis muscle
and removed from the animal for cellular assessment. The electrodes were placed on the anterior
15

surface of the muscle as medial as possible. Drops of saline
(PBS) were applied to the surface of the muscle and the
incision was covered with plastic saran wrap to prevent
desiccation. Once the muscle was properly exposed and
positioned, a 30-minute wait period was completed to allow
for the vasculature to equilibrate. Utilizing QCapture Pro
software, photomicrographs were captured at 10x
magnification of the collateral at rest, following functional

Figure 6. Muscle contraction via
electrode stimulation.
An electrode is placed on the anterior
medial section of the gracilis muscle
containing the collateral arteriole. Constant
current muscle stimulation is completed to
simulate the cardiovascular response that
occurs with exercise and assess vessel
functionality.

dilation, where it was electrically stimulated with an
electrode to promote muscle contraction (FVD), and following pharmacological treatment with
sodium nitroprusside (SNP) and norepinephrine (NE) to determine maximum dilating and
constricting capacity of the collateral, respectively. For the FVD part of the procedure, two
tungsten electrodes were placed gently on the gracilis anterior in the midzone section between
the saphenous and profunda arteries (Figure 7). The muscle was subject to constant current
stimulation of 1mA for 90 seconds at a frequency of 8 Hz. Cyan LED transilluminators were
used to illuminate collaterals under a compound brightfield microscope (Olympus BXFM). The
procedure was repeated on the opposite hindlimb. The order in which the FVD was performed
was randomized for operated and sham-operated hindlimbs for all replicates.
Measurements
ImageJ software was used to measure diameters of the collateral vessels for the operated
hindlimb of each experimental group (DIO-Cell, DIO-Vehicle, Lean-Cell, and Lean-Vehicle) at
resting state and functionally vasodilated state. The percent difference of collateral diameter size
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between resting state and functionally vasodilated state was calculated for the operated hindlimb
of each experimental group sample. See appendix B for further details on measurement method.
Statistical Analysis
Two-way ANOVA tests were run to determine differences between groups, and when applicable,
a Box Cox transformation of the data was performed (Minitab). Tukey Post-Hoc and interaction
comparisons were also made for some tests. Data are presented as mean ± standard error.

RESULTS
This line of research aims to develop an alternative, minimally invasive, therapy to treat patients
with ischemic diseases that would benefit from natural bypass enlargement. In this study, we
tested the hypothesis that myoblasts enhance arteriogenesis, following femoral artery ligation
surgery (n=12) and implantation of bio printed construct containing myoblasts (n=6) or vehicle
control (n=6). Collaterals were exposed and imaged 7 days post-surgery to determine the impact
of myoblasts on diameter. Myoblasts did not enhance collateral diameters following functional
vasodilation. Mice that received the cell transplant (lean: 91.3 ± 5.00μm, DIO: 83.82 ± 1.35μm)
were not different than those that received the vehicle control (78.02 ± 4.00μm and 91.88 ±
2.13μm, respectively). To evaluate how collateral vasodilation is affected by mouse phenotype
(DIO) collateral diameters were compared between resting (Figure 7a) and dilated (Figure 7b)
states of lean mice and mice with DIO. Myoblasts increased collateral diameters in lean mice
(92.3 ± 0.29μm) compared to vehicle control (72.44 ± 0.80μm), meanwhile myoblasts decreased
collateral diameter in mice with DIO (77.72 ± 1.76μm) when compared to vehicle control (93.16
± 0.19μm). Nonetheless, no differences in diameter size were found when comparing resting and
functionally vasodilated operated collaterals, for all mice (Figure 7c).
17

Figure 7. Vasodilation is impaired in mice with DIO
No differences in diameter size were observed between resting (A) and functionally vasodilated
(B) collaterals of lean mice and mice with DIO. Nonetheless, mice with DIO presented a decrease
in collateral diameter when treated with myoblasts whereas lean mice presented an increase in
diameter when treated with myoblasts. The data suggests that myoblasts may increase vascular
maturity (tone) in DIO mice. Cell-phenotype interaction may impact collateral vessel diameter in
the operated hindlimb. Data are presented as mean ± standard error.

To determine if myoblasts impact collateral vasodilation following arteriogenesis, the percent
difference between resting and functionally vasodilated collateral diameter was calculated.
Myoblasts increased the percent difference (Figure 8c) between resting (Figure 8a) and
functionally vasodilated (Figure 8b) collaterals in mice with diet induced obesity. Myoblast
transplantation yielded the greatest percent differences in mice with DIO (16.29 ± 9.95%)
compared to its vehicle sham (8.71 ± 3.55%). The inverse affect was shown in lean mice where
myoblast transplantation (3.92 ± 1.54%) yielded a the smallest percent difference compared to its
vehicle sham (12.20 ± 8.99%).
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Figure 8. Myoblasts increase vascular reactivity in mice with DIO
Percent differences in diameter size between resting (A) and functionally vasodilated (B) collaterals
were the highest for mice with DIO that received myoblast treatment (n=3). The interaction of
mouse phenotype and cell treatment influences percent difference of diameter size between resting
and functionally vasodilated collaterals. DIO mice receiving myoblast treatment (n=3) yielded a
larger percent difference compared to DIO mice receiving vehicle-sham treatment (n=3). Lean mice
receiving myoblast treatment (n=3) yielded a smaller percent difference compared to lean mice
receiving vehicle-sham treatment (n=3). Data are presented as mean ± standard error.

DISCUSSION
Peripheral Artery Occlusive Disease affects approximately 6.5 million people aged 40 and older
in the United States2,3,4,5. This circulatory disease involves narrowed arteries, reducing blood
flow to limbs and resulting in chronic ischemia8. Increasing the blood flow to those extremities is
possible by allowing the blood to flow through natural bypass collateral arteries. This study was
conducted using animal models and in-vivo surgical procedures to investigate the potential for
cell therapy, particularly the administration of muscle progenitor cells (i.e. myoblasts), to treat
patients with PAOD. Objectives include determining the impact of myoblasts on arteriogenesis
and vasodilation.
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Myoblasts did not enhance arteriogenesis in this study. Interestingly, mouse phenotype, i.e. dietinduced obesity, also did not impair arteriogenesis. Vasodilation was impaired in all mice
following ligation, regardless of phenotype or myoblast transplantation. Normally, electrical
stimulation of skeletal muscle contraction induces a metabolic vasodilation in which the
collateral diameter enlarges up to two times its resting diameter, as observed in the shamoperated hindlimb collateral for all mice (Appendix D). Myoblasts increased collateral diameter
in lean mice, but decreased collateral diameter in mice with DIO. A reason for this may include
myoblast interaction with the endothelial lining of the vessel walls. Endothelial dysfunction is an
onset symptom of obesity24. In healthy tissues, perivascular adipose tissue secretes (PVAT)
factors that increase nitric oxide availability and influence vasodilation25. In obese subjects,
PVAT releases pro-contractile factors that instead lead to endothelial dysfunction. Endothelial
network formation is improved however, when higher numbers of myoblasts are present26.
Because endothelial dysfunction is present in collaterals of obese mice, myoblasts may have had
a greater effect on these vessels over collaterals that do not need repair, collaterals of lean mice.
This can explain why smaller collateral diameters are seen in obese mice; these vessels may have
matured sooner due to the increased incentive brought on by obesity, and the increased
opportunity that comes with the presence of myoblasts. Vessel maturity describes the extent to
which a blood vessel has developed27 and improvements in development include a vessel’s
contractile activity (i.e. vascular tone)28. We know that these vessels, however, did not develop
vascular tone because there were no differences found between resting and FVD collateral
diameters. This concept is worth investigating further in future studies to determine myoblast
effect on collateral diameter of lean and obese mice and the vessels’ ability to mature and
develop vascular tone.
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Reactivity was measured as the percent difference of a collateral’s FVD diameter from its resting
diameter. Myoblasts increased reactivity in mice with DIO. Myoblasts alone did not impact
collateral vasodilation following arteriogenesis, rather only in the obese mouse phenotype.
Limitations to this study involved inaccurate representation of obese phenotype and difficulty in
placing the bio-printed construct. As previously described in the methods section, the mice were
given a 1:1 mixture of standard mouse feed and specialized feed depending on their experimental
group, control feed (10% fat) for lean mice (n=6), or treatment feed (60% fat) for mice with DIO
(n=6). The intended ratio for mouse feed was supposed to be 100% control feed for lean mice
and 100% treatment feed for mice with DIO, rather than the 50%-50% implemented. This error
resulted in phenotype discrepancies between experimental groups, however, due to time and
resource constraints the study commenced despite this error. It was noted that only half of the
mice receiving the treatment feed gained enough weight to be considered obese (>38g). Two of
the mice that exceeded the weight limit received the vehicle control, while the other mouse was a
part of the cell treatment group (51.2g, 48g, and 43g, respectively). All remaining mice receiving
the treatment feed and the mice receiving the control lean feed weighed between 30.5 – 37.3g.
Statistical analysis was completed with samples categorized under their assigned experimental
group, despite the majority of the mice falling into the lean weight category (<38g). For future
studies, mouse phenotype classification should be confirmed prior to study commencement.
Secondly, placement of the bio-printed cell or vehicle-control construct may have been
inconsistent due to complications in construct disintegration while handling and/or visualization
after placement. Localization of the construct underneath the gracilis pocket would be
inconsistent because of these challenges, leading to an inaccurate supply of myoblasts, less
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release of paracrine factors, resulting in less effect. This can impact the degree of arteriogenesis
of the collateral and/or vessel functionality.
CONCLUSION
Despite these limitations, we found that myoblasts did not enhance arteriogenesis, vasodilation is
impaired mice with DIO, and that myoblasts increase vascular reactivity (i.e. more percent
difference between resting and functionally vasodilated collateral diameters) in mice with DIO.
Continued studies should evaluate myoblast effect on vascular tone in lean mice compared to
mice with DIO. Specifically determining whether vascular tone is increased in mice with DIO, as
observed in this study. Eventually, this line of research will benefit PAOD patients by providing
an alternative, minimally invasive, therapy to treat their symptoms of chronic ischemia and
improve their quality of life.
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APPENDICES
Appendix A: Surgery and Experimental Protocols
Femoral Artery Ligation Protocol
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Ambulation Scoring Protocol
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Functional Vasodilation Protocol
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Femoral Artery Ligation Set Up

Functional Vasodilation Set Up
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Appendix B: Measurement Method
To calibrate the scale of the measurements, a photo of a 1x1mm microscope micrometer was
taken using the same microscope under the same magnification as the photomicrographs. Three
separate measurements were taken along the same vessel and the average was recorded as the
final diameter size. This measurement process was repeated for every samples vessel (n=12) at
each of the four conditional states (rest, FVD, SNP, and NE).
Appendix C: Sample Raw Images
C57Bl/6 Male Replicate 1
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C57Bl/6 Male Replicate 2

C57Bl/6 Male Replicate 3
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C57Bl/6 Male Replicate 4

C57Bl/6 Male Replicate 5
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C57Bl/6 Male Replicate 6

C57Bl/6 Male Replicate 7
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C57Bl/6 Male Replicate 8

C57Bl/6 Male Replicate 9
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C57Bl/6 Male Replicate 10

C57Bl/6 Male Replicate 11
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C57Bl/6 Male Replicate 12
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Appendix D: Raw Data
C57Bl/6 Functional Vasodilation Data
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Appendix E: Statistical Analysis
Two – way ANOVA #1
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Two – way ANOVA with Box Cox Transformation
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Two – way ANOVA #2
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